Publikation

Bone morphogenic protein-4 availability in the cardiac microenvironment controls inflammation and fibrosis in autoimmune myocarditis.

Wissenschaftlicher Artikel/Review - 19.02.2024

Bereiche
PubMed
DOI
Kontakt

Zitation
Pérez Shibayama C, Gil Cruz C, Cadosch N, Lütge M, Cheng H, De Martin A, Frischmann K, Joachimbauer A, Onder L, Papadopoulou I, Papadopoulou C, Ring S, Krebs P, P. Vu V, P. Nägele M, Rossi V, Parianos D, Zsilavecz V, Cooper L, Flammer A, Ruschitzka F, Rainer P, Schmidt D, Ludewig B. Bone morphogenic protein-4 availability in the cardiac microenvironment controls inflammation and fibrosis in autoimmune myocarditis. Nat Cardiovasc Res 2024; 3:301-316.
Art
Wissenschaftlicher Artikel/Review (Englisch)
Zeitschrift
Nat Cardiovasc Res 2024; 3
Veröffentlichungsdatum
19.02.2024
eISSN (Online)
2731-0590
Seiten
301-316
Kurzbeschreibung/Zielsetzung

Myocarditis is an inflammatory heart disease that leads to loss of cardiomyocytes and frequently precipitates fibrotic remodeling of the myocardium, culminating in heart failure. However, the molecular mechanisms underlying immune cell control and maintenance of tissue integrity in the inflamed cardiac microenvironment remain elusive. In this study, we found that bone morphogenic protein-4 (BMP4) gradients maintain cardiac tissue homeostasis by single-cell transcriptomics analyses of inflamed murine and human myocardial tissues. Cardiac BMP pathway dysregulation was reflected by reduced BMP4 serum concentration in patients with myocarditis. Restoration of BMP signaling by antibody-mediated neutralization of the BMP inhibitors gremlin-1 and gremlin-2 ameliorated T cell-induced myocardial inflammation in mice. Moreover, progression to inflammatory cardiomyopathy was blocked through the reduction of fibrotic remodeling and preservation of cardiomyocyte integrity. These results unveil the BMP4-gremlin axis as a druggable pathway for the treatment of myocardial inflammation, limiting the severe sequelae of cardiac fibrosis and heart failure.